DrugRisk Update: Yaz Settlements Reach Nearly 5,000, Will Continue For Now
The Drug Resource Center is the premiere source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.
Salt Lake City, UT (PRWEB) March 07, 2013
The drug safety advocates at DrugRisk.com are alerting those who have taken the birth control Yaz or Yasmin of updated information on the site showing the drug maker Bayer has settled nearly 5,000 blood clot cases, and will continue to review new claims for settlement.
“DrugRisk´s goal is to improve patient safety by providing the most recent information on drug warnings, recalls, studies and litigation news. Many visitors who have taken Yaz or Yasmin are concerned whether Bayer is still compensating blood clot victims,” explains DrugRisk representative Ryan Mayer.
The resource center contains studies from the British Medical Journal and FDA which previously warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.*
DrugRisk has also discovered that thousands of Yaz lawsuits filed by patients have been consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
Now, the latest financial statements from Bayer uncovered by DrugRisk show the company faces as many as 13,600 Yaz side effects claimants.** Bayer also disclosed they have settled around 4,800 claims involving blood clot injuries like deep vein thrombosis (DVT) or pulmonary embolism, for a cost of around $1 billion.**
The drug maker advises investors that they will continue to evaluate blood clot claims for settlement on a case-by-case basis.** Fortunately, patients who have suffered blood clot injuries but have yet to file a case can still do so.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
Due to the specialized nature of the federal MDL court and litigation process, DrugRisk cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, “Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints”
**Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebyasmin-lawsuit/yaz-recall/prweb10504685.htm